ATLASCytoMed Therapeutics (GDTC) earnings date: expected February 4–10
CytoMed Therapeutics (GDTC) has not announced its next earnings date yet. Based on its last 3 reports, ATLAS expects it around February 4–10. That is an estimate, not a confirmed date.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on GDTC
| Last price | $0.92 (+2.0%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.4% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 4 reports |
These figures come from the same calibrated model and valuation as the CytoMed Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Expected around February 4–10 (estimate). One email the day before, with ATLAS’s read on CytoMed Therapeutics. You can switch it off at any time.
Alert me before GDTC reportsFree to start. Creating an account takes under a minute.
GDTC earnings at a glance
| Next report | Not announced · expected around February 4–10 (ATLAS estimate) |
|---|---|
| Last report | May 27, 2026 · In line |
| Beat rate (last 4 reports) | 2 of 4 (50%) |
| Average EPS surprise | -32.4% |
| Average move around a report | ±6.6% (last 4) |
| Sector | Healthcare · Biotechnology |
The expected window is an ATLAS estimate: it takes the typical gap between CytoMed Therapeutics’s last 3 reports and adds it to the most recent one. Companies announce the real date a few weeks ahead, and ATLAS switches the page to the confirmed date as soon as it is published.
CytoMed Therapeutics earnings history: last 4 reports
CytoMed Therapeutics last reported on May 27, 2026: EPS of $2.90 against an estimate of $2.91 (-0.3% surprise), in line with the estimate.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| May 27, 2026 | $2.91 | $2.90 | -0.3% | In line | -0.9% |
| Jan 15, 2026 | $2.98 | $3.14 | +5.4% | Beat | +1.9% |
| Nov 18, 2025 | $0.25 | $0.33 | +32.0% | Beat | -8.6% |
| Sep 14, 2025 | $0.03 | -$0.02 | -166.7% | Miss | -15.0% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for GDTC
See the fair value, the probability range and the earnings history of CytoMed Therapeutics on its ATLAS page.
CytoMed Therapeutics (GDTC) stock analysisPlans from €3.99 a month.
CytoMed Therapeutics earnings: frequently asked questions
When is CytoMed Therapeutics (GDTC) next earnings date?
CytoMed Therapeutics has not announced its next report. Its last 3 reports came May 27, 2026, Jan 15, 2026, Sep 14, 2025, so ATLAS estimates the next one around February 4–10. This is an estimate based on that pattern, not a confirmed date.
How often does GDTC beat earnings estimates?
Of its last 4 reports with a recorded result, CytoMed Therapeutics beat the EPS estimate 2 times; the average surprise was -32.4%. Past results do not predict the next one.
How much does GDTC move around earnings?
Over its last 4 reports the stock moved an average of 6.6% (absolute, from the close before the report day to the close after it), and finished higher 1 of 4 times.
Did CytoMed Therapeutics beat earnings estimates last quarter?
CytoMed Therapeutics last reported on May 27, 2026: EPS of $2.90 against an estimate of $2.91 (-0.3% surprise), in line with the estimate.
How much does GDTC usually move in a day?
On a normal trading day the ATLAS model puts GDTC’s one-day range at about ±4.4%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Educational information, not investment advice. Disclaimer